
LabGenius develops next-generation antibody and protein therapeutics to improve selectivity and tumor cell killing. The company applies a machine learning–driven evolution engine (EVA) that combines artificial intelligence, synthetic biology, and robotic automation to design, evolve, and screen antibody sequences. EVA is modality- and format-agnostic and supports LabGenius’s internal pipeline focused on selectivity-enhanced antibodies for solid tumors. The platform integrates ML models, high-throughput wet lab automation, and synthetic construct libraries to accelerate discovery and lead optimization. LabGenius advances a pipeline of therapeutic antibody candidates toward clinical development for oncology.

LabGenius develops next-generation antibody and protein therapeutics to improve selectivity and tumor cell killing. The company applies a machine learning–driven evolution engine (EVA) that combines artificial intelligence, synthetic biology, and robotic automation to design, evolve, and screen antibody sequences. EVA is modality- and format-agnostic and supports LabGenius’s internal pipeline focused on selectivity-enhanced antibodies for solid tumors. The platform integrates ML models, high-throughput wet lab automation, and synthetic construct libraries to accelerate discovery and lead optimization. LabGenius advances a pipeline of therapeutic antibody candidates toward clinical development for oncology.
Founded: 2012 (London)
Core technology: EVA — ML-driven, highly automated antibody discovery platform
Therapeutic focus: Selectivity-enhanced antibodies for solid tumours
Business model: Hybrid — internal pipeline plus strategic partnerships
Latest funding: £35M Series B (May 21, 2024); total funding reported £58M
Antibody and protein therapeutic discovery and optimisation for oncology (solid tumours).
2012
Biotechnology Research
£35 million
Announced Series B on May 21, 2024; company stated total funding to date reached £58M.
$10 million
Reported Series A in October 2019 with participation from Felicis Ventures, Inovia Capital, Air Street Capital and others.
“Backed by institutional venture investors including M Ventures, Lux Capital, Obvious Ventures, Atomico, Octopus Ventures, LG Corp, Kindred Capital, Lux Capital and others.”
| Company |
|---|
At LabGenius, our mission is to accelerate the discovery of next-generation therapeutic antibodies. We have pioneered the development of EVA™, a smart robotic platform capable of designing, conducting, and learning from its own experiments.
For our wholly-owned pipeline, we are using our closed-loop discovery engine to establish a pipeline of highly selective T-cell engagers and ADCs for the treatment of solid tumors.
LabGenius has raised over £58M and is backed by top-tier investors, including M Ventures, Octopus Ventures, LG Corp, Atomico, Kindred Capital, Lux Capital, and Obvious Ventures, among others. The company is headquartered in London (UK), where we have established a state-of-the-art antibody engineering facility staffed by a multidisciplinary team of more than 50 scientists and engineers.
Senior Software Engineer Software Engineering London Hybrid Full-time
Financial:
Health:
Time-Off:
Wellbeing:
Team-building:
We believe that diversity makes for innovative, exceptional teams. We are an equal opportunity employer and do not discriminate based on gender, race, color, religion or belief, national origin, age, sexual orientation, marital status, disability, or any other protected class.
If you don't feel like you meet every single requirement of this role, we still want to hear from you! We encourage you to apply and have a discussion with us about the role or others that we may have at LabGenius now or in the future. Together, we can build more inclusive workplaces.